EMA–FDA Joint Q&A on Quality and GMP Aspects of PRIME/Breakthrough Therapy Applications 22-01-2024
The EMA’s PRIority MEdicines (PRIME) scheme and the FDA’s Breakthrough Therapy (BT) designation program are designed to expedite the development of innovative products that address unmet medical needs. However, the…